Evidence map›Paper›PMID 38107178›Full record

ArticleRSC medicinal chemistry2023

Discovery of novel tubulin CBSI

Zhipeng Huo, Delin Min, Shijie Zhang, Mei-Lin Tang, Xun Sun

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zhipeng HuoDepartment of Natural Medicine, School of Pharmacy, Fudan University 826 Zhangheng Road Shanghai 201203 China tangmeilin@fudan.edu.cn sunxunf@shmu.edu.cn.
Delin MinDepartment of Natural Medicine, School of Pharmacy, Fudan University 826 Zhangheng Road Shanghai 201203 China tangmeilin@fudan.edu.cn sunxunf@shmu.edu.cn.
Shijie ZhangDepartment of Natural Medicine, School of Pharmacy, Fudan University 826 Zhangheng Road Shanghai 201203 China tangmeilin@fudan.edu.cn sunxunf@shmu.edu.cn.
Mei-Lin TangDepartment of Natural Medicine, School of Pharmacy, Fudan University 826 Zhangheng Road Shanghai 201203 China tangmeilin@fudan.edu.cn sunxunf@shmu.edu.cn.
Xun SunDepartment of Natural Medicine, School of Pharmacy, Fudan University 826 Zhangheng Road Shanghai 201203 China tangmeilin@fudan.edu.cn sunxunf@shmu.edu.cn.ORCID https://orcid.org/0000-0002-4316-2988
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In view of the serious adverse reactions and clinical toxicity of first line therapy 5-fluorouracil and lack of small molecule therapeutics in colorectal cancer chemotherapy, a series of natural scaffold-based 3-arylindanone derivatives (9a-q) were designed, synthesized and evaluated as tubulin polymerization inhibitors targeting the colchicine site. The most potent colchicine binding site inhibitor (CBSI),

Identifiers

PMID38107178
PMCPMC10718523
OpenAlexW4386806364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.